by Ray Holder » Sun Apr 22, 2007 5:29 am
I have just seen this posting on the BMJ website. it seems others have the same thought. The clip follows---
Should you tell patients about beneficial treatments that they cannot have? Yes
Marcus (21 April 2007) [Full text] [PDF]
Should you tell patients about beneficial treatments that they cannot have? Yes
Take the case of macular degeneration 22 April 2007
Celine M Aranjo,
Senior G.P.
NSW, Australia 2208
Send response to journal:
Re: Take the case of macular degeneration
Someone (age unknown) is going blind because of macular degeneration (MD) The treatment is available but at his own expense not at the cost of the NHS. This is the story so far. How many more are there with similar stories?
Is there anyone who is interested in the causes of macular degeneration, also occurring in the 'aged' other than 'age-related macular degeneration'(AMD)?
In my limited experience, there are many 'aged' persons who have been prescribed and are taking regular doses of statins. Post-marketing surveys proclaim in no uncertain terms that statins can and do cause peripheral neuropathies, and is it not the fact that retinal neurons are the peripheral ends of the optic nerves?
It is to be wondered epidemiologically, how many AMD cases are taking a statin drug.
Furthermore, would it not be prudent to stop the offending drug and await regeneration of the neurons, if no irreversible damage has occurred? And what then if the new treatment is carried out at great expense, and the offending etiological factor has not been recognised and stopped?
Competing interests: None declared
*************************************************************
Ray